• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Healthcare, regulatory and reimbursement landscape - Mexico

Report: Healthcare, regulatory and reimbursement landscape - Mexico

September 14, 2012
CenterWatch Staff

Industry analysis specialist GlobalData has released its new report, Healthcare, Regulatory and Reimbursement Landscape – Mexico, which identifies the key trends in the Mexican healthcare market, as well as providing insights on the demographic, regulatory and reimbursement landscape, and the healthcare infrastructure of Mexico.

Most importantly, the report provides valuable insights on the trends and segmentation of the pharmaceutical and medical devices market. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by a team of industry experts.

The population of Mexico in 2010 was approximately 112 million and was the 11th-most populated country in the world, and is increasing due to the country's high birth rate and increase in life expectancy.

The pharmaceutical market in Mexico was estimated at $11.4 billion in 2010 and is expected to reach approximately $22.5 billion by 2020 at a projected CAGR of 7%. The medical device market size was approximately $3 billion in 2010 and is expected to reach approximately $4.9 billion by 2020 at a projected CAGR of 5.2%.

According to GlobalData’s report, the positive trend in the Mexican healthcare market can be attributed primarily to an increasing elderly population; government initiatives for the prevention and management of chronic diseases; the North American Free Trade Agreement, which guarantees its members the protection of intellectual property rights; and an improved and updated regulatory environment.

The report provides information on the healthcare, regulatory and reimbursement landscape of Mexico. Its scope includes an overview of the Mexican pharmaceutical and medical devices market including the market size, market segmentation, key drivers and barriers for the market. It also includes a profile and SWOT analysis of the major players in the pharmaceutical and medical devices market—Pfizer, Sanofi and Genomma Lab, F. Hoffmann-la Roche, Siemens Healthcare and Fresenius Medical.

In addition, the scope includes review on the reimbursement and regulatory landscape. Analysis includes details of the healthcare reimbursement process, regulatory agencies and market authorization process for new drug and medical devices for Mexico; a details of the political and economic environment of Mexico including economic indicators, demographics, healthcare infrastructure and healthcare expenditure; and an overview of the opportunities and challenges for growth that exist in the Mexican healthcare market.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing